5 Healthcare Stocks Under $10 Ready To Pop

In the second spot is Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), whose stock price is up by about 16% in August despite a meltdown in the stock market. The surge came on the heels of unconfirmed news that the company was engaged in merger talks with Baxalta Inc (NYSE:BXLT), which unfortunately didn’t come through, as an agreement about the price couldn’t be reached, according to rumors. However, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s stock is still up by almost 17% for the year. The company’s main cancer drug Iclusig is expected to add between $130 million and $140 million to the company’s top line this year. At the end of June a total of 31 hedge funds had an aggregate investment of $401.61 million in Ariad. Sarissa Capital Management, which is managed by Alex Denner, tops our list of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s investors, as it holds about 12.85 million shares valued at $106.27 million.